Eli Lilly and Company is a global leader in pharmaceuticals, focusing on discovering, developing, and marketing a wide range of human medications. With a rich history dating back to 1876 and headquartered in Indianapolis, Indiana, it offers treatments for diabetes, including a comprehensive lineup of insulin products, and type 2 diabetes medications like Jardiance and Trulicity. The company also has a strong presence in oncology, rheumatoid arthritis, dermatology, mental health, and more, with notable products such as Alimta for cancer and Cymbalta for depression. Eli Lilly collaborates with various industry partners to enhance its product offerings.
Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipeline and valuation reveals why…
Vandita Jadeja Employer coverage of GLP-1 drugs is collapsing heading into 2027, but the FDA just gave Eli Lilly a specific piece of ammunition that could change the conversation in payer meetings for at…
Omor Ibne Ehsan Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.
OpenAI just built an AI-designed chip that already beats Nvidia's best in early tests, and one macro investor has pinpointed exactly when Nvidia's most valuable competitive advantage disappears entirely.
Employer insurance coverage for GLP-1 weight-loss drugs is shrinking, yet Eli Lilly just posted a 47% revenue surge. Something underneath the headlines is keeping volumes alive, and it changes how shareholders should…
Omor Ibne Ehsan Eli Lilly and Novo Nordisk both dominated GLP-1 headlines in Q2 2026, but one company raised guidance while the other announced layoffs, pipeline writedowns, and a dramatic price cut. The split screen…
Eli Lilly just crossed a $1 trillion market cap for the first time, and management is already pointing toward a milestone that would rewrite the drugmaker's history. Whether three converging pipeline catalysts…
Eli Lilly just delivered one of the most staggering quarters in Big Pharma history, yet Wall Street is barely reacting. Three catalysts in the next 18 months could either push shares to…
Lilly, Novo, and Merck have each priced in a radically different version of the next two years, and one of them looks like a setup where the market has it badly wrong.
Eli Lilly just became the first pharmaceutical company ever valued above $1 trillion, yet analysts who dig into its pipeline are arguing the market still has not grasped what the next two…
A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why.
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to…
Jim Cramer called packaged food stocks 'so hated' right now, but the data behind the sentiment tells a more complicated story that could catch contrarian buyers off guard.
Vanguard swapped the benchmark powering one of the most popular growth ETFs on the market, and most holders never saw it coming. What looks like a paperwork formality could quietly reshape which…
Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to…
